Mark Borden

Dr. Mark Borden

orcid

Research Focus & Metrics

Academic Career Length

22Years (2005-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 June 2014 in Advanced Drug Delivery Reviews
Verified
Journal Article
Closed access
SSShashank R. Sirsi
Shashank R. Sirsi
MBMark Borden
Mark Borden

1 January 2018 in Theranostics
Verified
Journal Article
Open access
KSKang-Ho Song
Kang-Ho Song
BHBrandon K. Harvey
Brandon K. Harvey
MBMark Borden
Mark Borden
Focused ultrasound with microbubbles promises unprecedented advantages for blood-brain barrier disruption over existing intracranial drug delivery methods, as well as a significant number of tunable parameters that affect its safety and efficacy. This review provides an engineering perspective on the state-of-the-art of the technology, considering the mechanism of action, effects of microbubble properties, ultrasound parameters and physiological variables, as well as safety and potential therapeutic applications. Emphasis is placed on the use of unified parameters, such as microbubble volume dose (MVD) and ultrasound mechanical index, to optimize the procedure and establish safety limits. It is concluded that, while efficacy has been demonstrated in several animal models with a wide range of payloads, acceptable measures of safety should be adopted to accelerate collaboration and improve understanding and clinical relevance.

1 January 2012 in Journal of Controlled Release
Verified
Journal Article
Closed access
SSShashank R. Sirsi
Shashank R. Sirsi
SHSonia L. Hernandez
Sonia L. Hernandez
LZLukasz Zielinski
Lukasz Zielinski
HBHenning Blomback
Henning Blomback
AKAdel Koubaa
Adel Koubaa
MBMark Borden
Mark Borden

1 July 2015 in Journal of Controlled Release
Verified
Journal Article
Closed access
SFSamantha M. Fix
Samantha M. Fix
MBMark Borden
Mark Borden
PDPaul Dayton
Paul Dayton

1 January 2017 in Theranostics
Verified
Journal Article
Open access
KSKang-Ho Song
Kang-Ho Song
AFAlexander C. Fan
Alexander C. Fan
JHJoshua J. Hinkle
Joshua J. Hinkle
JNJoshua Newman
Joshua Newman
MBMark Borden
Mark Borden
BHBrandon Keith Harvey
Brandon Keith Harvey
Focused ultrasound with microbubbles is being developed to transiently, locally and noninvasively open the blood-brain barrier (BBB) for improved pharmaceutical delivery. Prior work has demonstrated that, for a given concentration dose, microbubble size affects both the intravascular circulation persistence and extent of BBB opening. When matched to gas volume dose, however, the circulation half-life was found to be independent of microbubble size. In order to determine whether this holds true for BBB opening as well, we independently measured the effects of microbubble size (2 vs. 6 µm diameter) and concentration, covering a range of overlapping gas volume doses (1-40 µL/kg). We first demonstrated precise targeting and a linear dose-response of Evans Blue dye extravasation to the rat striatum for a set of constant microbubble and ultrasound parameters. We found that dye extravasation increased linearly with gas volume dose, with data points from both microbubble sizes collapsing to a single line. A linear trend was observed for both the initial sonication (R2=0.90) and a second sonication on the contralateral side (R2=0.68). Based on these results, we conclude that microbubble gas volume dose, not size, determines the extent of BBB opening by focused ultrasound (1 MHz, ~0.5 MPa at the focus). This result may simplify planning for focused ultrasound treatments by constraining the protocol to a single microbubble parameter - gas volume dose - which gives equivalent results for varying size distributions. Finally, using optimal parameters determined for Evan Blue, we demonstrated gene delivery and expression using a viral vector, dsAAV1-CMV-EGFP, one week after BBB disruption, which allowed us to qualitatively evaluate neuronal health.

19 January 2011 in Contrast Media & Molecular Imaging
Verified
Journal Article
Open access
PDF file
LMLee Mullin
Lee Mullin
RGRyan Gessner
Ryan Gessner
JKJames Kwan
James Kwan
Mehmet KayaMehmet Kaya
Mehmet Kaya
MBMark Borden
Mark Borden
PDPaul Dayton
Paul Dayton
Purpose: Microbubble contrast agents are currently implemented in a variety of both clinical and preclinical ultrasound imaging studies. The therapeutic and diagnostic capabilities of these contrast agents are limited by their short in‐vivo lifetimes, and research to lengthen their circulation times is on going. In this manuscript, observations are presented from a controlled experiment performed to evaluate differences in circulation times for lipid shelled perfluorocarbon‐filled contrast agents circulating within rodents as a function of inhaled anesthesia carrier gas.Methods: The effects of two common anesthesia carrier gas selections ‐ pure oxygen and medical air were observed within five rats. Contrast agent persistence within the kidney was measured and compared for oxygen and air anesthesia carrier gas for six bolus contrast injections in each animal. Simulations were performed to examine microbubble behavior with changes in external environment gases.Results: A statistically significant extension of contrast circulation time was observed for animals breathing medical air compared to breathing pure oxygen. Simulations support experimental observations and indicate that enhanced contrast persistence may be explained by reduced ventilation/perfusion mismatch and classical diffusion, in which nitrogen plays a key role by contributing to the volume and diluting other gas species in the microbubble gas core.Conclusion: Using medical air in place of oxygen as the carrier gas for isoflurane anesthesia can increase the circulation lifetime of ultrasound microbubble contrast agents. Copyright © 2011 John Wiley & Sons, Ltd.